Free Trial

Adaptimmune Therapeutics (ADAP) Competitors

$1.28
+0.04 (+3.23%)
(As of 07/12/2024 ET)

ADAP vs. FATE, PGEN, BLUE, CLLS, ATRA, SANA, VIR, TARS, AUTL, and IMTX

Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Fate Therapeutics (FATE), Precigen (PGEN), bluebird bio (BLUE), Cellectis (CLLS), Atara Biotherapeutics (ATRA), Sana Biotechnology (SANA), Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), and Immatics (IMTX). These companies are all part of the "medical" sector.

Adaptimmune Therapeutics vs.

Adaptimmune Therapeutics (NASDAQ:ADAP) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.

Adaptimmune Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

In the previous week, Fate Therapeutics had 1 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Adaptimmune Therapeutics. Fate Therapeutics' average media sentiment score of 1.19 beat Adaptimmune Therapeutics' score of 0.92 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Adaptimmune Therapeutics Positive
Fate Therapeutics Positive

Adaptimmune Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$60.28M5.24-$113.87M-$0.74-1.73
Fate Therapeutics$63.53M6.47-$160.93M-$1.92-1.88

Adaptimmune Therapeutics has a net margin of -890.13% compared to Fate Therapeutics' net margin of -2,933.79%. Fate Therapeutics' return on equity of -46.49% beat Adaptimmune Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics-890.13% -259.68% -61.31%
Fate Therapeutics -2,933.79%-46.49%-34.48%

Adaptimmune Therapeutics presently has a consensus price target of $2.79, suggesting a potential upside of 117.77%. Fate Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 86.98%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Fate Therapeutics
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21

31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fate Therapeutics received 171 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 68.67% of users gave Fate Therapeutics an outperform vote while only 62.42% of users gave Adaptimmune Therapeutics an outperform vote.

CompanyUnderperformOutperform
Adaptimmune TherapeuticsOutperform Votes
309
62.42%
Underperform Votes
186
37.58%
Fate TherapeuticsOutperform Votes
480
68.67%
Underperform Votes
219
31.33%

Summary

Fate Therapeutics beats Adaptimmune Therapeutics on 10 of the 18 factors compared between the two stocks.

Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAP vs. The Competition

MetricAdaptimmune TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$315.94M$3.00B$5.40B$8.73B
Dividend YieldN/A2.11%2.77%4.03%
P/E Ratio-1.7312.59108.9715.72
Price / Sales5.24311.562,183.7683.88
Price / CashN/A169.7836.4333.15
Price / Book7.533.914.944.46
Net Income-$113.87M-$44.32M$111.51M$215.59M
7 Day Performance4.92%8.76%6.20%5.35%
1 Month Performance26.73%-1.15%5.71%4.39%
1 Year Performance42.06%-5.18%6.49%1.77%

Adaptimmune Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.7783 of 5 stars
4.78 / 5 stars
$3.12
-0.3%
$6.75
+116.3%
-26.6%$355.15M$63.53M-1.62181Short Interest ↓
Positive News
PGEN
Precigen
3.4291 of 5 stars
3.43 / 5 stars
$1.54
-0.6%
$10.00
+549.4%
+36.4%$388.73M$6.22M-3.95202
BLUE
bluebird bio
1.74 of 5 stars
1.74 / 5 stars
$1.04
+4.0%
$5.46
+425.2%
-63.1%$113.71M$3.60M-1.41323Positive News
CLLS
Cellectis
2.4156 of 5 stars
2.42 / 5 stars
$1.95
+1.6%
$8.00
+310.3%
-11.4%$108.38M$9.19M-1.51231Gap Down
ATRA
Atara Biotherapeutics
3.5164 of 5 stars
3.52 / 5 stars
$9.02
+11.4%
$700.00
+7,660.5%
-79.0%$43.48M$8.57M-0.17334Short Interest ↑
News Coverage
Positive News
SANA
Sana Biotechnology
1.6064 of 5 stars
1.61 / 5 stars
$5.18
-1.0%
$12.75
+146.1%
+0.3%$1.15BN/A-3.39328News Coverage
VIR
Vir Biotechnology
2.8428 of 5 stars
2.84 / 5 stars
$8.37
flat
$34.14
+307.9%
-59.9%$1.14B$86.18M-2.09587Short Interest ↓
News Coverage
Positive News
TARS
Tarsus Pharmaceuticals
1.4043 of 5 stars
1.40 / 5 stars
$28.20
-0.3%
$50.38
+78.6%
+67.9%$1.07B$17.45M-5.91244Positive News
AUTL
Autolus Therapeutics
2.688 of 5 stars
2.69 / 5 stars
$3.93
+3.4%
$8.70
+121.4%
+68.7%$1.05B$10.50M-3.27463Short Interest ↑
IMTX
Immatics
1.2632 of 5 stars
1.26 / 5 stars
$12.10
-1.2%
$16.00
+32.2%
+14.0%$1.04B$74.47M-11.42432Positive News

Related Companies and Tools

This page (NASDAQ:ADAP) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners